These tools will no longer be maintained as of December 31, 2024. Archived website can be found here. PubMed4Hh GitHub repository can be found here. Contact NLM Customer Service if you have questions.


Pubmed for Handhelds

PUBMED FOR HANDHELDS

Journal Abstract Search

632 related items for PubMed ID: 11765724

  • 1. Imatinib mesylate.
    Am J Health Syst Pharm; 2001 Dec 01; 58(23):2241-2. PubMed ID: 11765724
    [No Abstract] [Full Text] [Related]

  • 2. STI571: an inhibitor of the BCR-ABL tyrosine kinase for the treatment of chronic myelogenous leukaemia.
    O'Dwyer ME, Druker BJ.
    Lancet Oncol; 2000 Dec 01; 1():207-11. PubMed ID: 11905636
    [Abstract] [Full Text] [Related]

  • 3. Chronic myelogenous leukaemia--new therapeutic principles.
    O'Dwyer ME, Druker BJ.
    J Intern Med; 2001 Jul 01; 250(1):3-9. PubMed ID: 11454136
    [Abstract] [Full Text] [Related]

  • 4. Imatinib mesylate in the treatment of chronic myeloid leukaemia.
    Druker BJ.
    Expert Opin Pharmacother; 2003 Jun 01; 4(6):963-71. PubMed ID: 12783592
    [Abstract] [Full Text] [Related]

  • 5. Chronic myeloid leukemia. Sceptical scientists.
    Druker BJ.
    Lancet; 2001 Dec 01; 358 Suppl():S11. PubMed ID: 11784560
    [No Abstract] [Full Text] [Related]

  • 6. A Bcr/Abl kinase antagonist for chronic myelogenous leukemia: a promising path for progress emerges.
    Sausville EA.
    J Natl Cancer Inst; 1999 Jan 20; 91(2):102-3. PubMed ID: 9923844
    [No Abstract] [Full Text] [Related]

  • 7.
    ; . PubMed ID:
    [No Abstract] [Full Text] [Related]

  • 8.
    ; . PubMed ID:
    [No Abstract] [Full Text] [Related]

  • 9. Dragons 'round the fleece again: STI571 versus alpha1 acid glycoprotein.
    Sausville EA.
    J Natl Cancer Inst; 2000 Oct 18; 92(20):1626-7. PubMed ID: 11036101
    [No Abstract] [Full Text] [Related]

  • 10.
    ; . PubMed ID:
    [No Abstract] [Full Text] [Related]

  • 11. STI571 (Gleevec) as a paradigm for cancer therapy.
    Druker BJ.
    Trends Mol Med; 2002 Oct 18; 8(4 Suppl):S14-8. PubMed ID: 11927282
    [Abstract] [Full Text] [Related]

  • 12.
    ; . PubMed ID:
    [No Abstract] [Full Text] [Related]

  • 13.
    ; . PubMed ID:
    [No Abstract] [Full Text] [Related]

  • 14.
    ; . PubMed ID:
    [No Abstract] [Full Text] [Related]

  • 15. Targeting the BCR-ABL tyrosine kinase in chronic myeloid leukemia.
    Goldman JM, Melo JV.
    N Engl J Med; 2001 Apr 05; 344(14):1084-6. PubMed ID: 11287980
    [No Abstract] [Full Text] [Related]

  • 16. Taking aim at Ewing's sarcoma: is KIT a target and will imatinib work?
    Druker BJ.
    J Natl Cancer Inst; 2002 Nov 20; 94(22):1660-1. PubMed ID: 12441314
    [No Abstract] [Full Text] [Related]

  • 17.
    ; . PubMed ID:
    [No Abstract] [Full Text] [Related]

  • 18. Gleevec: tailoring to fit.
    May TS.
    Drug Discov Today; 2003 Mar 01; 8(5):188-9. PubMed ID: 12634004
    [No Abstract] [Full Text] [Related]

  • 19.
    ; . PubMed ID:
    [No Abstract] [Full Text] [Related]

  • 20. Inhibition of the Bcr-Abl tyrosine kinase as a therapeutic strategy for CML.
    Druker BJ.
    Oncogene; 2002 Dec 09; 21(56):8541-6. PubMed ID: 12476300
    [No Abstract] [Full Text] [Related]

    Page: [Next] [New Search]
    of 32.